The thesis
PanicFade v4 bets on a well-documented behavioural quirk: markets overreact to bad news. When a name gets hit by negative headline sentiment (below -0.4) while already technically oversold — RSI14 under 35 and trading below its 20-day moving average — the strategy buys into the panic and sizes up as the selling continues. It exits on reversion (RSI14 back above 50, or price reclaiming the SMA20) and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The design is grounded in recent sentiment-asymmetry literature (arXiv:2509.11970, 2025, plus corroborating JRFM work), and it keeps the plumbing conservative: live-quote-only cash accounting, sanity-banded stops, and data-verified rotation. The universe is 24 mega-cap and large-cap names across tech, financials, healthcare, staples, and energy — liquid enough that a contrarian can actually get filled.
Recent activity
Since the Season 2 reset to $10,000 on 29 October, the strategy has been active but cautious — typically one to three executions per scheduled run, with zero rejections. Trading has clustered in CAT, GOOGL, NVDA, and BAC. The CAT activity is instructive: a buy at $622.54 (30 Oct) was sold at $613.49 (2 Nov), a rebuy at $621.97 (3 Nov) sold at $585.79 (4 Nov), then another buy at $561.74 (5 Nov) — a run of whipsaw as the name kept making lower lows rather than reverting. GOOGL round-tripped more happily ($280.28 → $282.94).
The scoreboard reflects that chop. Total equity has drifted from $10,000 down to $9,712.88 by 5 November — roughly a 2.9% drawdown in the first week live. Nothing alarming, but it is a reminder that fading panic sometimes means catching a falling knife before reversion arrives.
Backtest and validation
Over 1,233 days the strategy returned 37.93% (final equity $13,793), a 6.79% CAGR, with a Sharpe of 0.96, a 9.3% max drawdown, and a 62.88% win rate across 530 trades. The validation is the strongest part of the story: four walk-forward folds, all four positive, with out-of-sample metrics (21.7% return, 2.44 Sharpe on the most recent fold) that actually exceed the in-sample average. The Probabilistic Sharpe Ratio of 0.985 is excellent, and the Deflated Sharpe of 0.56 — after a 27-trial multiple-testing haircut — still clears the bar.
Verdict
Strengths: genuinely clean validation (positive in every regime from 2021's bear market onward), a high win rate, and a shallow drawdown profile. The deflated Sharpe surviving 27 trials is reassuring against overfitting.
Risks: the headline 37.93% flatters a 6.79% annualised return, and the overall 0.96 Sharpe is only ordinary. Turnover of 5,807% is enormous — this strategy lives and dies on execution costs, and $530 of fees on $10k of notional is not trivial drag. Fold 4 carried the OOS result; the earlier folds were thin (1.6% and 3.88%). And the live start, while early, is underwater on exactly the whipsaw its hard-stops are meant to survive. Promising, well-governed, but prove it in the open.